STOCK TITAN

DENTSPLY SIRONA (XRAY) SEC Filings, Oct 15, 2025

XRAY NASDAQ

DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.

The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.

Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.

The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
insider
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On 10/10/2025, the SVP, Chief Supply Chain Office reported 972.381 shares of common stock acquired at $0, credited as dividends on restricted stock units that vest with the underlying awards and convert 1:1 into common stock.

The filing also reports 40.5116 phantom stock units under the SERP acquired at $11.98, each economically equivalent to one share and payable in stock upon termination of employment. Following these entries, direct ownership stands at 124,187.521 common shares and 3,072.9326 phantom stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
insider
-
Form 4
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported a routine insider update: Director Janet S. Vergis acquired 179.449 additional common shares on 10/10/2025, recorded at $0, from dividend equivalents on previously granted restricted stock units (RSUs). The acquisition is coded “A.”

Following the transaction, her beneficial ownership stands at 44,300.167 common shares, held directly. The filing notes these credits reflect RSU dividend equivalents that vest on the same schedule as the related RSUs, with each RSU converting to one share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Form 4
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.

Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported insider equity accruals. Officer Richard C. Rosenzweig received 766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.

He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.

The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.

Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary

DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.

On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Form 4
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.

The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) reported an insider equity change by director Betsy D. Holden. On 10/10/2025, the filing lists Common Stock acquired under code “A” totaling 646.937 at $0. The footnote explains these reflect dividend equivalents on restricted stock units (RSUs) credited as additional RSUs, which vest on the same schedule as the underlying awards, and each RSU converts to common stock on a 1:1 basis. Following the transaction, Holden beneficially owned 53,902.896 shares, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Form 4
Rhea-AI Summary

DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none

FAQ

How many DENTSPLY SIRONA (XRAY) SEC filings are available on StockTitan?

StockTitan tracks 147 SEC filings for DENTSPLY SIRONA (XRAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for DENTSPLY SIRONA (XRAY)?

The most recent SEC filing for DENTSPLY SIRONA (XRAY) was filed on November 16, 2026.